Status:
COMPLETED
Effects of Combined Resveratrol and Myo-inositol on Altered Metabolic, Endocrine Parameters and Perceived Stress in Patients With Polycystic Ovarian Syndrome
Lead Sponsor:
Khyber Medical University Peshawar
Conditions:
PCOS
Eligibility:
FEMALE
20-35 years
Phase:
PHASE2
Brief Summary
The investigators aim is to conduct a double blind randomized clinical trial, to study the effects of combined Resveratrol and Myo-Inositol on altered metabolic, endocrine parameters and perceived str...
Detailed Description
Polycystic ovarian syndrome (PCOS) is extremely prevalent and considered to be the most common heterogeneous endocrine disorder in reproductive age women. This affects up to 10-15% of women in reprodu...
Eligibility Criteria
Inclusion
- Treatment naive PCOS women having age from 14-45 years with scanty or no menstruation, hirsutism and elevated serum androgen levels, will be diagnosed on the basis of AES (Androgen access society) guidelines 2006 according to which when two of the following criteria are present patient will be said to have the syndrome
- Hirsutism or hyperandrogenism
- Oligo or an-ovulation and or polycystic ovaries
Exclusion
- Women with previous history of Cushing syndrome
- Thyroid disorders
- Hyperprolactinemia
- Ovarian tumors
- Congenital adrenal hyperplasia androgen-producing tumors,
- History of seizures
- Patients on warfarin, Coumadin and Sintrom because of drug interaction with acetyl-L-Carnitine,
- Pregnancy or using contraceptive medications,
- Patients on hormonal therapy that alters the biochemical or hormonal profile
Key Trial Info
Start Date :
May 3 2021
Trial Type :
INTERVENTIONAL
Allocation :
ACTUAL
End Date :
August 3 2021
Estimated Enrollment :
88 Patients enrolled
Trial Details
Trial ID
NCT04867252
Start Date
May 3 2021
End Date
August 3 2021
Last Update
September 13 2021
Active Locations (1)
Enter a location and click search to find clinical trials sorted by distance.
1
Gynecology and Obstetric, Hayatabad Medical Complex
Peshawar, Khyber Pukhtunkhwa, Pakistan, 25000